BIANCHINI, Filippo, Virginia CRIVELLI, Morgan E. ABERNATHY, Concetta GUERRA, Martin PALUS, Jonathan MURI, Harold MARCOTTE, Antonio PIRALLA, Mattia PEDOTTI, Raoul DE GASPARO, Luca SIMONELLI, Milos MATKOVIC, Chiara TOSCANO, Maira BIGGIOGERO, Veronica CALVARUSO, Pavel SVOBODA, Tomás CERVANTES RINCÓN, Tommaso FAVA, Lucie PODEŠVOVÁ, Akanksha A. SHANBHAG, Andrea CELORIA, Jacopo SGRIGNANI, Michal STEFANIK, Václav HÖNIG, Veronika PRANCLOVA, Tereza MICHALCIKOVA, Jan PROCHAZKA, Giuditta GUERRINI, Dora MEHN, Annalisa CIABATTINI, Hassan ABOLHASSANI, David JARROSSAY, Mariagrazia UGUCCIONI, Donata MEDAGLINI, Qiang PAN-HAMMARSTRÖM, Luigi CALZOLAI, Daniel FERNANDEZ, Fausto BALDANTI, Alessandra FRANZETTI-PELLANDA, Christian GARZONI, Radislav SEDLACEK, Daniel RŮŽEK, Luca VARANI, Andrea CAVALLI, Christopher O. BARNES a Davide F. ROBBIANI. Human neutralizing antibodies to cold linear epitopes and subdomain 1 of the SARS-CoV-2 spike glycoprotein. Science Immunology. American Association for the Advancement of Science, 2023, roč. 8, č. 81, s. 1-17. ISSN 2470-9468. Dostupné z: https://dx.doi.org/10.1126/sciimmunol.ade0958.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Human neutralizing antibodies to cold linear epitopes and subdomain 1 of the SARS-CoV-2 spike glycoprotein
Autoři BIANCHINI, Filippo, Virginia CRIVELLI, Morgan E. ABERNATHY, Concetta GUERRA, Martin PALUS (203 Česká republika), Jonathan MURI, Harold MARCOTTE, Antonio PIRALLA, Mattia PEDOTTI, Raoul DE GASPARO, Luca SIMONELLI, Milos MATKOVIC, Chiara TOSCANO, Maira BIGGIOGERO, Veronica CALVARUSO, Pavel SVOBODA (203 Česká republika, domácí), Tomás CERVANTES RINCÓN, Tommaso FAVA, Lucie PODEŠVOVÁ, Akanksha A. SHANBHAG, Andrea CELORIA, Jacopo SGRIGNANI, Michal STEFANIK, Václav HÖNIG (203 Česká republika), Veronika PRANCLOVA, Tereza MICHALCIKOVA, Jan PROCHAZKA, Giuditta GUERRINI, Dora MEHN, Annalisa CIABATTINI, Hassan ABOLHASSANI, David JARROSSAY, Mariagrazia UGUCCIONI, Donata MEDAGLINI, Qiang PAN-HAMMARSTRÖM, Luigi CALZOLAI, Daniel FERNANDEZ, Fausto BALDANTI, Alessandra FRANZETTI-PELLANDA, Christian GARZONI, Radislav SEDLACEK, Daniel RŮŽEK (203 Česká republika, domácí), Luca VARANI, Andrea CAVALLI, Christopher O. BARNES a Davide F. ROBBIANI.
Vydání Science Immunology, American Association for the Advancement of Science, 2023, 2470-9468.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30102 Immunology
Stát vydavatele Spojené státy
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 24.800 v roce 2022
Kód RIV RIV/00216224:14310/23:00130433
Organizační jednotka Přírodovědecká fakulta
Doi http://dx.doi.org/10.1126/sciimmunol.ade0958
UT WoS 000957715600004
Klíčová slova anglicky SARS-CoV-2; coronavirus; vaccines; antiviral monoclonal antibodies
Štítky rivok
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Mgr. Marie Šípková, DiS., učo 437722. Změněno: 2. 6. 2023 14:04.
Anotace
Emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants diminishes the efficacy of vaccines and antiviral monoclonal antibodies. Continued development of immunotherapies and vaccine immunogens resilient to viral evolution is therefore necessary. Using coldspot-guided antibody discovery, a screening approach that focuses on portions of the virus spike glycoprotein that are both functionally relevant and averse to change, we identified human neutralizing antibodies to highly conserved viral epitopes. Antibody fp.006 binds the fusion peptide and cross-reacts against coronaviruses of the four genera, including the nine human coronaviruses, through recognition of a conserved motif that includes the S2′ site of proteolytic cleavage. Antibody hr2.016 targets the stem helix and neutralizes SARS-CoV-2 variants. Antibody sd1.040 binds to subdomain 1, synergizes with antibody rbd.042 for neutralization, and, similar to fp.006 and hr2.016, protects mice expressing human angiotensin-converting enzyme 2 against infection when present as a bispecific antibody. Thus, coldspot-guided antibody discovery reveals donor-derived neutralizing antibodies that are cross-reactive with Orthocoronavirinae, including SARS-CoV-2 variants.
VytisknoutZobrazeno: 27. 9. 2024 04:42